Mayo Clinic proceedings. Innovations, quality & outcomes · 2026
Supranormal Ejection Fraction as a Clinical Red Flag: Differentiating Hemodynamic Stress From Intrinsic Cardiomyopathy in Heart Failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yanjia, Su Xiuxiu, Jiang Jie, Tang Jing, Qiu Zeping, Yang Wenbo, Jin Wei
Аннотация
OBJECTIVE: To show that heart failure with supranormal ejection fraction (HFsnEF, left ventricular ejection fraction [LVEF] ≥ 65%) is not a marker of cardiac health but a specific enrichment zone for malignant cardiomyopathies and to provide a phenotypic framework for differential diagnosis.
PATIENTS AND METHODS: We retrospectively analyzed 200 consecutive patients with HFsnEF admitted between December 1, 2017 and December 1, 2024. Patients were stratified into 2 phenotypes based on etiology: group A (hemodynamic loading, n=88), comprising valvular or hypertensive heart disease; and group B (intrinsic cardiomyopathy, n=112), comprising hypertrophic cardiomyopathy, cardiac amyloidosis, or Fabry disease. We compared their electromechanical profiles and event-free survival.
RESULTS: Despite identical LVEF (median, 69%), the 2 groups exhibited distinct clinical signatures. Group A represented a classic secondary remodeling profile (older age and atrial fibrillation). In contrast, group B patients were younger (56.0 vs 68.8 years; P<.001) yet displayed severe diastolic stiffness (septal E/e' > 13) and a distinct electromechanical fingerprint (wide QRS or PR deviations). In a fully adjusted multivariable Cox model, the intrinsic cardiomyopathy phenotype was the dominant driver of the composite end point (adjusted hazards ratio, 3.91; 95% CI, 1.71-8.93; P = .001). Notably, N-terminal pro-B-type natriuretic peptide was not an independent predictor (P = .20) in this population, indicating that structural etiology overrides hemodynamic biomarkers in determining prognosis.
CONCLUSION: An LVEF of 65% or more is not reassuring but signals underlying heterogeneity, often masking malignant intrinsic cardiomyopathies that masquerade as benign heart failure with preserved ejection fraction. A multimodal red flag approach-integrating clinical, imaging, and electrocardiographic data-is essential to trigger targeted evaluation, as standard heart failure with preserved ejection fraction management is insufficient for these high-risk phenotypes.
PATIENTS AND METHODS: We retrospectively analyzed 200 consecutive patients with HFsnEF admitted between December 1, 2017 and December 1, 2024. Patients were stratified into 2 phenotypes based on etiology: group A (hemodynamic loading, n=88), comprising valvular or hypertensive heart disease; and group B (intrinsic cardiomyopathy, n=112), comprising hypertrophic cardiomyopathy, cardiac amyloidosis, or Fabry disease. We compared their electromechanical profiles and event-free survival.
RESULTS: Despite identical LVEF (median, 69%), the 2 groups exhibited distinct clinical signatures. Group A represented a classic secondary remodeling profile (older age and atrial fibrillation). In contrast, group B patients were younger (56.0 vs 68.8 years; P<.001) yet displayed severe diastolic stiffness (septal E/e' > 13) and a distinct electromechanical fingerprint (wide QRS or PR deviations). In a fully adjusted multivariable Cox model, the intrinsic cardiomyopathy phenotype was the dominant driver of the composite end point (adjusted hazards ratio, 3.91; 95% CI, 1.71-8.93; P = .001). Notably, N-terminal pro-B-type natriuretic peptide was not an independent predictor (P = .20) in this population, indicating that structural etiology overrides hemodynamic biomarkers in determining prognosis.
CONCLUSION: An LVEF of 65% or more is not reassuring but signals underlying heterogeneity, often masking malignant intrinsic cardiomyopathies that masquerade as benign heart failure with preserved ejection fraction. A multimodal red flag approach-integrating clinical, imaging, and electrocardiographic data-is essential to trigger targeted evaluation, as standard heart failure with preserved ejection fraction management is insufficient for these high-risk phenotypes.